6 min read

PrecivityAD2 vs. Quest AD-Detect vs. Labcorp: Comparing Alzheimer's Blood Tests

Compare PrecivityAD2, Quest AD-Detect, and Labcorp Alzheimer's blood tests: biomarkers measured, cutoffs, physician ordering, costs, and trial acceptance.

By Tokei Health, Cognitive Health Editorial Team

Free 3-Minute Online Check · Instant Score

Draw the 11:10 clock on screen or upload a photo of a paper sheet — no signup required.

Start Free Screen & Trial Check

Once you start researching Alzheimer's blood tests, the naming gets confusing fast. Patients and caregivers hear about PrecivityAD2, Quest AD-Detect, and Labcorp's p-tau217 and ATN panels—all marketed around detecting brain amyloid or Alzheimer's pathology from a blood draw, yet priced and reported very differently.

Understanding what each assay actually measures, how it handles borderline results, and how neurologists use it can help you have a sharper conversation with your doctor and avoid paying for a test that does not answer your clinical question.

Why Not All Alzheimer's Blood Tests Are Built the Same

Early Alzheimer's blood tests relied primarily on measuring beta-amyloid 42/40 (Aβ42/40) in plasma. While useful, the difference in blood Aβ42/40 levels between someone with brain plaques and someone without is relatively small (often around 10% to 15%), making the test sensitive to lab handling and biological noise.

Newer blood panels center on p-tau217—which rises dramatically (often several-fold) when amyloid plaques are present—or combine p-tau217 with Aβ42/40 and neurodegeneration markers like neurofilament light chain (NfL).

Side-by-Side Comparison: PrecivityAD2 vs. Quest AD-Detect vs. Labcorp

The table below summarizes how the three most frequently discussed U.S. clinical blood biomarker options compare across markers, ordering pathways, reporting styles, and specialist adoption.

| Feature | C2N PrecivityAD2 | Quest AD-Detect (p-tau217 & Amyloid Panels) | Labcorp (p-tau217 & ATN Profile) | | :--- | :--- | :--- | :--- | | Core Biomarkers Measured | Mass spectrometry p-tau217 ratio (p-tau217 / np-tau217) + Aβ42/40 ratio, combined into APS2 score (0–100). | Modular options: standalone p-tau217, Aβ42/40 ratio, p-tau181, or multi-marker panels (including ApoE isoform options). | Standalone p-tau217 assay, plus the ATN Profile (Aβ42/40, p-tau181/p-tau217 options, and NfL for neurodegeneration). | | Ordering Pathway | Clinician-ordered only (physician, NP, or PA evaluating cognitive impairment). | Clinician-ordered at any Quest draw site; select panels also available via consumer-initiated physician-reviewed ordering. | Clinician-ordered through standard Labcorp patient service centers. | | Cutoffs & Indeterminate Zone | Reports APS2 (0–100) using a validated single cutoff (often around 47.5) with no formal intermediate gray zone in standard reporting, though clinicians still weigh scores near the threshold carefully. | Typically uses a two-cutoff (three-zone) model for p-tau217: Negative, Indeterminate (intermediate), and Positive. | Standalone p-tau217 uses three-zone (Negative, Intermediate, Positive) reporting; ATN Profile reports each A/T/N component individually. | | Typical Cost & Coverage | Higher list price (often ~$1,200–$1,450 self-pay list), with income-based financial assistance and expanding payer/Medicare pathways. | Lower typical cash price for standalone tests (often ~$200–$400 depending on panel); insurance coverage varies by plan and medical necessity. | Competitive reference-lab pricing; insurance reimbursement varies by payer, diagnostic coding, and specific panel selected. | | Neurology & Clinical Trial Acceptance | Widely published in top peer-reviewed journals; strongly recognized by academic memory centers and frequently referenced in trial pre-screening discussions. | Broad accessibility across community primary care and neurology due to Quest's nationwide draw network; p-tau217 is favored over standalone Aβ42/40. | Widely accessible in community and specialty clinics; ATN Profile is valued when doctors want NfL to check for non-Alzheimer's neuronal injury. |

Deep Dive Into Each Testing Option

1. C2N PrecivityAD2 (APS2)

PrecivityAD2 is developed by C2N Diagnostics and uses liquid chromatography–tandem mass spectrometry (LC-MS/MS) to measure two ratios simultaneously: the plasma Aβ42/40 ratio and the p-tau217 ratio (phosphorylated tau 217 divided by non-phosphorylated tau 217). Those measurements feed into a proprietary algorithm that outputs an Amyloid Probability Score 2 (APS2) from 0 to 100.

  • Key strength: Using a ratio for p-tau217 helps buffer against false elevations caused by reduced kidney function, and pairing it with Aβ42/40 delivered roughly 90%+ accuracy against amyloid PET in published primary care and specialty cohorts.
  • Practical limitation: It requires a clinician's order, a specialized sample collection workflow, and careful verification of out-of-pocket costs or financial assistance eligibility beforehand.

2. Quest Diagnostics AD-Detect

Quest Diagnostics offers a family of AD-Detect blood tests rather than one single panel. Historically, Quest first launched a consumer-accessible Aβ42/40 blood test, which sparked debate among neurologists because standalone Aβ42/40 has lower precision than p-tau217. Since then, Quest expanded AD-Detect to include plasma p-tau217 and combination panels.

  • Key strength: Convenience and nationwide draw-site availability. If your primary care doctor orders Quest's p-tau217 assay specifically (rather than standalone Aβ42/40 alone), you get a widely recognized, high-sensitivity triage marker.
  • Practical limitation: Consumer-initiated tests can leave patients anxious if an indeterminate or positive result arrives in a web portal without a neurologist ready to interpret it alongside cognitive testing and brain imaging.

3. Labcorp p-tau217 and ATN Profile

Labcorp offers both targeted p-tau217 testing and its broader ATN Profile (Amyloid, Tau, Neurodegeneration). Including neurofilament light chain (NfL)—the "N" in ATN—adds a distinct clinical angle.

  • Key strength: NfL is not specific to Alzheimer's disease; it rises in many forms of nerve cell injury, including frontotemporal dementia, vascular injury, or inflammatory conditions. If a patient has normal amyloid/tau markers but elevated NfL, that tells a neurologist to keep looking for a non-Alzheimer's neurological cause.
  • Practical limitation: Multi-marker profiles can occasionally produce mixed signals (for example, one borderline marker and two normal markers) that still require specialist interpretation or confirmatory imaging.

Which Test Should You Ask Your Doctor About?

Rather than focusing solely on brand names, clinicians generally recommend asking three practical questions:

  1. Does the panel include p-tau217? In current neurology practice, assays anchored by p-tau217 (or a p-tau217 ratio) are strongly preferred over standalone Aβ42/40 or p-tau181 tests when evaluating possible Alzheimer's disease.
  2. Do I have documented cognitive symptoms? Blood biomarker testing is designed for adults with measurable cognitive concerns (such as MCI or mild dementia). Before ordering expensive lab work, doctors typically document baseline performance using brief cognitive checks. You can prepare for that conversation with our printable Clock Drawing Test or check what prior screening scores mean using the score interpreter.
  3. What happens if the result is indeterminate or positive? Ask in advance whether your clinic has a clear pathway for confirmatory amyloid PET, brain MRI, or referral to a memory specialist or clinical research center.

A Note on Clinical Trials

If cost or insurance denial is a barrier, remember that clinical trials frequently conduct their own high-precision blood biomarker testing (and confirmatory PET scans) at no cost to eligible participants. Even if you already have a Quest, Labcorp, or PrecivityAD2 report, a research site will still run its own central-lab validation—though having prior results can help a study coordinator determine whether a full screening visit makes sense.

If you are weighing cognitive testing and want to see how an objective self-check fits into clinical trial readiness, you can try the Tokei Health cognitive self-check for trial exploration.

Important Safety Reminder

Never start, stop, or adjust prescription medications based on a direct-to-consumer or clinic blood biomarker report. Blood tests detect biological risk markers—they do not replace a comprehensive neurological exam or rule out reversible contributors to memory loss such as sleep apnea, thyroid disease, B12 deficiency, or medication side effects.

Educational notice: Tokei Health (Coadia, Inc.) builds educational cognitive self-check software and plain-English resources. It is not a medical provider and does not diagnose, treat, or provide medical advice.

Frequently Asked Questions

What is the main difference between PrecivityAD2 and Quest AD-Detect?
PrecivityAD2 (from C2N Diagnostics) uses mass spectrometry to combine two ratios—the p-tau217 ratio and the Aβ42/40 ratio—into a single Amyloid Probability Score 2 (APS2) with a binary cutoff and requires a healthcare provider's order. Quest AD-Detect offers modular blood tests, including a standalone p-tau217 assay and an Aβ42/40 ratio test, through both physician ordering and consumer-initiated channels.
Which Alzheimer's blood test is more accurate: p-tau217 or Aβ42/40?
Across major clinical validation cohorts, plasma p-tau217 (and p-tau217 ratio assays) consistently outperform standalone Aβ42/40 blood tests for detecting brain amyloid plaques, because Aβ42/40 has a narrower fold-change between amyloid-positive and amyloid-negative individuals.
Can I order an Alzheimer's blood test without seeing a neurologist first?
Some national reference labs offer consumer-initiated options where an independent physician network reviews and authorizes the lab order. However, major specialty panels like PrecivityAD2 require a direct order from your own clinician, and all biomarker results should be interpreted by a doctor alongside cognitive testing.
Do clinical trials accept outside PrecivityAD2 or Quest blood test results?
Outside blood test results are helpful context during pre-screening and can guide referrals to research sites, but almost all Alzheimer's clinical trials still perform their own standardized central-lab blood draw and/or confirmatory amyloid PET scan to determine formal eligibility.
What is Labcorp's ATN Profile?
Labcorp's ATN Profile is a multi-marker blood panel designed around the Amyloid (A), Tau (T), and Neurodegeneration (N) research framework, combining Aβ42/40, phosphorylated tau, and neurofilament light chain (NfL) to give clinicians broader context on both Alzheimer's pathology and general neuronal injury.
Educational Self-Check

Take a 3-Minute Cognitive Baseline & Check Study Eligibility

Start with our free 3-minute clock & delayed recall screen, check reversible medication and sleep contributors, and optionally match with enrolling MCI and Alzheimer's studies near your ZIP code.

Start Free Screen & Trial Check

Free 3-minute clock check · No account required

Educational self-check software: Tokei Health (Coadia, Inc.) is not a healthcare provider and does not offer medical services, diagnosis, or medical advice. Always consult a qualified physician or pharmacist before making any health or medication decisions.